Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment
By Ben Glickman
Ligand Pharmaceuticals said its treatment for molluscum, a viral skin infection, had received approval from U.S. regulators.
The company said Friday that the U.S. Food and Drug Administration had approved Zelsuvmi, a topical prescription medication, to treat moluscum in adults and children one year old or older.
Ligand expects the treatment to be available in the U.S. in the second half of 2024.
The company said the FDA had approved Zelsuvmi as the first novel drug to treat mollescum infections.
Molluscum is a contagious skin infection which can cause lesions. It primarily affects children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 05, 2024 17:25 ET (22:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks